• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399

Recent Advances in the Study of tert-Butyl 4-(4-Aminopyrimidin-2-yl)piperazine-1-carboxylate (CAS: 1041054-18-5)

The compound tert-butyl 4-(4-aminopyrimidin-2-yl)piperazine-1-carboxylate (CAS: 1041054-18-5) has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile applications in drug discovery and development. Recent studies have focused on its role as a key intermediate in the synthesis of biologically active molecules, particularly in the development of kinase inhibitors and other therapeutic agents. This research brief aims to summarize the latest findings related to this compound, highlighting its synthetic utility, pharmacological potential, and emerging applications in targeted therapies.

One of the most notable advancements in the study of tert-butyl 4-(4-aminopyrimidin-2-yl)piperazine-1-carboxylate is its incorporation into the design of novel kinase inhibitors. Kinases play a critical role in cellular signaling pathways, and their dysregulation is implicated in various diseases, including cancer and inflammatory disorders. Researchers have successfully utilized this compound as a building block to develop selective inhibitors targeting specific kinases, such as JAK2 and PI3K, which are pivotal in oncogenic signaling. The structural flexibility of the piperazine-carboxylate moiety allows for fine-tuning of the inhibitor's selectivity and potency, making it a valuable scaffold in medicinal chemistry.

In addition to its role in kinase inhibitor development, recent studies have explored the compound's potential in other therapeutic areas. For instance, it has been investigated as a precursor for the synthesis of antiviral agents, particularly those targeting RNA viruses. The 4-aminopyrimidine moiety is known to interact with viral polymerases, and modifications of this scaffold have led to promising candidates with enhanced efficacy and reduced toxicity. Furthermore, the compound's stability and solubility profile make it an attractive candidate for further optimization in drug formulation.

The synthetic pathways for tert-butyl 4-(4-aminopyrimidin-2-yl)piperazine-1-carboxylate have also been refined in recent years, with a focus on improving yield and scalability. Green chemistry approaches, such as the use of catalytic methods and solvent-free reactions, have been employed to minimize environmental impact while maintaining high purity and efficiency. These advancements are critical for the large-scale production of the compound, ensuring its availability for both research and clinical applications.

Looking ahead, the continued exploration of tert-butyl 4-(4-aminopyrimidin-2-yl)piperazine-1-carboxylate holds great promise for the development of next-generation therapeutics. Its versatility as a synthetic intermediate, combined with its pharmacological potential, positions it as a cornerstone in the design of innovative drugs. Future research directions may include the exploration of its applications in combination therapies, as well as the development of derivatives with improved pharmacokinetic properties. As the field advances, this compound is likely to remain a focal point in the quest for novel and effective treatments for a wide range of diseases.

• 501126-08-5(1-Piperazinecarboxylic acid, 4-(5-ethyl-2-pyrimidinyl)-, 1,1-dimethylethylester)
• 924644-04-2(1-Piperazinecarboxylic acid, 4-(4-amino-2-pyrimidinyl)-, phenylmethylester)
• 99931-83-6(4-(2-pyrimidinyl)-1-Piperazinecarboxylic acid ethyl ester)
• 221050-88-0(Tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate)
• 221050-89-1(tert-Butyl 4-(pyrimidin-4-yl)-piperazine-1-carboxylate)
• 1272973-58-6(tert-Butyl 4-(5-hydroxypyrimidin-2-yl)piperazine-1-carboxylate)
• 780705-64-8(1-N-Boc-4-pyriMidin-2-yl-piperazine)
• 1353966-56-9(tert-Butyl 4-(6-(diethylamino)pyrimidin-4-yl)piperazine-1-carboxylate)
• 374930-88-8(Tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate)
• 436851-80-8(tert-Butyl 4-(6-aminopyrimidin-4-yl)piperazine-1-carboxylate)